Article Information
History
- November 4, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Brenna Kirka,
- Chris Busha,
- Astra Toyipa,
- Katherine E. Muesa,
- Ekkehard Beckb,*,
- Linwei Lib,
- Samantha St. Laurentb,
- Mihaela Georgievab,
- Morgan A. Marksb,
- Tianyu Sunb,
- Daina B. Espositob,
- David Martinb and
- Nicolas Van de Veldeb
- aAetion, Inc., 5 Pennsylvania Plaza, New York, NY 10001, USA
- bModerna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
- ↵*Corresponding Author:
Ekkehard Beck Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA Email: Ekkehard.Beck{at}modernatx.com
Posted November 04, 2023.
Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥65 years in the United States
